durvalumab (Imfinzi) with enfortumab vedotin-ejfv (Padcev) (Imfinzi/Padcev): FDA status

Under review Under review Nov 13, 2026. Indication: Perioperative (neoadjuvant and adjuvant) treatment of cisplatin ineligible or refused muscle invasive bladder cancer. Company: AstraZeneca / Pfizer.

Regulatory history

All products in the FDA Tracker

Loading today's edition…